Kornitzer Capital Management Inc. KS Sells 14,500 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Kornitzer Capital Management Inc. KS lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 97,262 shares of the medical research company’s stock after selling 14,500 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in IQVIA were worth $23,048,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Versant Capital Management Inc increased its holdings in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in IQVIA during the 2nd quarter valued at approximately $27,000. Park Place Capital Corp bought a new position in IQVIA in the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. purchased a new stake in IQVIA during the 2nd quarter valued at approximately $29,000. Finally, International Assets Investment Management LLC purchased a new position in shares of IQVIA in the second quarter worth $32,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Performance

NYSE IQV traded down $0.24 on Thursday, hitting $221.01. 349,218 shares of the company’s stock traded hands, compared to its average volume of 1,093,375. The firm has a market capitalization of $40.11 billion, a PE ratio of 29.03, a P/E/G ratio of 2.15 and a beta of 1.51. IQVIA Holdings Inc. has a 1-year low of $190.20 and a 1-year high of $261.73. The firm’s 50-day moving average price is $232.31 and its two-hundred day moving average price is $229.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analysts Set New Price Targets

Several research analysts have commented on IQV shares. UBS Group lifted their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday. TD Cowen cut their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and decreased their price target for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Finally, Barclays cut their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $259.13.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.